D. Medical Receives CE Mark Approval for "Spring Zone" Durable Insulin Pump
D. Medical Industries Ltd. (Nasdaq: DMED) today announced that the Company, through its wholly owned subsidiary Spring Health Solution Ltd., received a CE Mark approval for its Spring™ Zone Insulin Delivery System. "Spring Zone" replaces D. Medical's first generation Spring ADI insulin pump.
The proprietary Intellispring™ technology at the heart of the "Spring Zone" Insulin Delivery System results in unique performance advantages such as superior blockage and detachment detection, environmental (pressure and temperature) adaptability and continuous insulin dose delivery check. This mechanism, backed by the Total Line Control™ (TLC) safety check system, enables failsafe operation and exceptional reliability for continuously controlled and monitored insulin delivery.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.